You are here

  • Home
  • Archive
  • Volume 77, Issue 11
  • Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis

Article info

Article menu
Download PDFPDF
Letter
Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis

Authors

  • Yi-Ming Chen Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Faculty of Medicine, National Yang Ming University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  • Tsai-Ling Liao Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  • Hsin-Hua Chen Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan Faculty of Medicine, National Yang Ming University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  • Der-Yuan Chen Department of Medicine, Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan Department of Medical Research, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan School of Medicine, China Medical University, Taichung, Taiwan PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Der-Yuan Chen, Department of Medicine, Rheumatology and Immunology Center, China Medical University Hospital, Taichung 40447, Taiwan; dychen1957{at}gmail.com
View Full Text

Citation

Chen Y, Liao T, Chen H, et al
Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases 2018;77:1688-1689.

Publication history

  • Received January 23, 2018
  • Revised March 22, 2018
  • Accepted April 2, 2018
  • First published April 19, 2018.
Online issue publication 
April 04, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.